80 related articles for article (PubMed ID: 7831376)
1. Cost-effectiveness of HA-1A treatment for patients with sepsis.
van Hout BA; Birnie E; Redekop WK; Lorijn RH; Bossuyt PM; Rutten FF
Prog Clin Biol Res; 1994; 388():435-43. PubMed ID: 7831376
[TBL] [Abstract][Full Text] [Related]
2. [Cost-effectiveness analysis of human monoclonal antibody HA-1A in patients with sepsis syndrome].
Van Hout BA; Rutten FF; Lorijn RH
Ned Tijdschr Geneeskd; 1993 Feb; 137(7):360-4. PubMed ID: 8437635
[TBL] [Abstract][Full Text] [Related]
3. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent.
Schulman KA; Glick HA; Rubin H; Eisenberg JM
JAMA; 1991 Dec; 266(24):3466-71. PubMed ID: 1744962
[TBL] [Abstract][Full Text] [Related]
5. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
Barriere SL; Guglielmo BJ
Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients.
Chalfin DB; Holbein ME; Fein AM; Carlon GC
JAMA; 1993 Jan; 269(2):249-54. PubMed ID: 8417245
[TBL] [Abstract][Full Text] [Related]
7. Projected impact of monoclonal anti-endotoxin antibody therapy.
Bates DW; Lee TH
Arch Intern Med; 1994 Jun; 154(11):1241-9. PubMed ID: 8203991
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of activated protein C in real-life clinical practice.
Dhainaut JF; Payet S; Vallet B; França LR; Annane D; Bollaert PE; Le Tulzo Y; Runge I; Malledant Y; Guidet B; Le Lay K; Launois R;
Crit Care; 2007; 11(5):R99. PubMed ID: 17822547
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands.
Postma MJ; van Hulst M; De Wolf JT; Botteman M; Staginnus U
Transfus Med; 2005 Oct; 15(5):379-87. PubMed ID: 16202052
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
[TBL] [Abstract][Full Text] [Related]
12. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
[TBL] [Abstract][Full Text] [Related]
13. The costs and cost-effectiveness of an integrated sepsis treatment protocol.
Talmor D; Greenberg D; Howell MD; Lisbon A; Novack V; Shapiro N
Crit Care Med; 2008 Apr; 36(4):1168-74. PubMed ID: 18379243
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy, safety, and therapeutic usage of HA-1A and E5 in the treatment of gram-negative sepsis.
Quintiliani R; Cooper B; Maderazo E; Nightingale C
Hosp Formul; 1992 Jan; 27(1):49-52, 54, 57-60. PubMed ID: 10116116
[TBL] [Abstract][Full Text] [Related]
15. The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin.
Arch Intern Med; 1994 Nov; 154(21):2484-91. PubMed ID: 7979845
[TBL] [Abstract][Full Text] [Related]
16. HA-1A. A human monoclonal antibody for the treatment of gram-negative sepsis.
Smith CR; Straube RC; Ziegler EJ
Infect Dis Clin North Am; 1992 Mar; 6(1):253-66. PubMed ID: 1578120
[TBL] [Abstract][Full Text] [Related]
17. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.
Kobelt G; Berg J; Lindgren P; Jonsson B; Stawiarz L; Hillert J
Mult Scler; 2008 Jun; 14(5):679-90. PubMed ID: 18566030
[TBL] [Abstract][Full Text] [Related]
18. Life-saving immunotherapy with cross-reactive monoclonal antibodies against endotoxin: a critical evaluation of experimental and clinical studies.
Cornelissen JJ; Schellekens JF; Kraaijeveld CA; Verhoef J
Neth J Med; 1991 Oct; 39(3-4):170-6. PubMed ID: 1791879
[TBL] [Abstract][Full Text] [Related]
19. [Cost effectiveness of captopril after myocardial infarct; comment].
Szucs T; Berger K; Schulte-Hillen J; Kleber FX
Med Klin (Munich); 1996 Feb; 91(2):112-8. PubMed ID: 8850108
[TBL] [Abstract][Full Text] [Related]
20. The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody.
Linden PK; Angus DC; Chelluri L; Branch RA
J Crit Care; 1995 Dec; 10(4):154-64. PubMed ID: 8924965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
